| Zoledronic acid. | |
| | |
MedLine Citation:
|
PMID: 21114419 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions. AREA COVERED IN THIS REVIEW: The incidence, clinical importance and prevention strategies to minimize side effects associated with the use of zoledronic acid are discussed with a particular focus on use in oncology where intensive monthly scheduling is required. This potentially increases the risk for adverse events over the 6-12 monthly administration used to treat benign bone diseases. WHAT THE READER WILL GAIN: A detailed understanding of the generally favorable safety profile of zoledronic acid, but particularly the potential for renal dysfunction and osteonecrosis of the jaw. TAKE HOME MESSAGE: When compared to many other therapies, especially in the cancer setting, the severity of adverse events related to zoledronic acid is generally mild and, with the exception of the acute phase response causing transient fever, myalgia and bone pain, side effects are infrequent. Thus, the benefits of treatment with zoledronic acid within its licensed indications almost always outweigh the risks. |
| | |
Authors:
|
Robert Coleman; Roger Burkinshaw; Matthew Winter; Helen Neville-Webbe; Jim Lester; Emma Woodward; Janet Brown |
Related Documents
:
|
12590939 - Phosphinic, phosphonic and seleninic acid bioisosteres of isonipecotic acid as novel an... 1635589 - Characterization of extracellular gaba in the substantia nigra reticulata by means of b... 7849419 - A practical synthesis of optically pure and fully protected l-gamma-carboxyglutamic aci... 1968959 - Comparison of transmitter amino acid levels in rat globus pallidus and neostriatum duri... 6123549 - In vitro release of endogenous beta-alanine, gaba, and glutamate, and electrophysiologi... 11803699 - Ntp summary report on the metabolism, disposition, and toxicity of 1,4-butanediol (cas ... 22303939 - Advances in the synthesis of bioactive unnatural amino acids and peptides. 21294819 - Enhanced solid-state citric acid bio-production using apple pomace waste through surfac... 487319 - Regional distribution of amino acids in friedreich's ataxia brains. |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-11-29 |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: 10 ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-16 Completed Date: 2011-03-31 Revised Date: 2011-08-25 |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 133-45 Citation Subset: IM |
Affiliation:
|
University of Sheffield, Weston Park Hospital, Academic Unit of Clinical Oncology, Sheffield, UK. r.e.coleman@sheffield.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Density Conservation Agents
/
adverse effects*,
therapeutic use* Bone Diseases / drug therapy Diphosphonates / adverse effects*, therapeutic use* Drug Toxicity Fractures, Bone / drug therapy Humans Imidazoles / adverse effects*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 118072-93-8/zoledronic acid |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: How do homeopaths reason and make decisions? Integrating theory, practice, and education.
Next Document: Signal transducer and activator of transcription 3 inhibitors: a patent review.